A Multi-Center ,Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of TPN171H in Patients With Erectile Dysfunction
Latest Information Update: 09 Mar 2023
Price :
$35 *
At a glance
- Drugs Simmerafil (Primary)
- Indications Erectile dysfunction
- Focus Registrational; Therapeutic Use
- Sponsors Vigonvita Life Sciences
- 06 Mar 2023 Status changed from recruiting to completed.
- 20 Jan 2022 Status changed from not yet recruiting to recruiting.
- 20 Jan 2022 New trial record